Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS
The Federal Circuit has ruled that Sandoz did not forfeit its preemption defence and the BPCIA preempts state law remedies in its biosimilars dispute with Amgen. The decision makes clear that brand biologic companies have no remedies available against a biosimilar applicant who is refusing to engage in the patent dance
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
